| Similar Articles |
|---|
 |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders?   |
The Motley Fool
September 18, 2006
Brian Lawler |
Cell Therapeutics' New Mate The biopharmaceutical company removes some uncertainty by teaming up with Novartis. Investors, take note. |
Registered Rep.
February 1, 2005
Bob Hirschfeld |
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
The Motley Fool
May 4, 2011
Brian Orelli |
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. |
BusinessWeek
September 29, 2003
Gene G. Marcial |
Taking Aim at Cancer Cell Therapeutics isn't expected to make money until 2007, but Edward Hemmelgarn, president of Shaker Investments, is buying into the small-cap biotech anyway. Shaker already owns 1.7 million shares. Cell is developing cancer treatments that are less toxic but more effective, he says. |
The Motley Fool
July 13, 2011
Sean Williams |
Shareholders Should Fire These 3 CEOs Is it time for these CEOs to step aside in the name of progress?: Antonio Perez of Kodak... Stephan Elop of Nokia... James Bianco of Cell Therapeutics... |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
January 4, 2012
Brian Orelli |
Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining. |
